Ionis Pharmaceuticals, Inc. — Q1 2016 Form 10-Q Summary
Business context and reporting period
Ionis Pharmaceuticals is an RNA-targeted therapeutics company developing antisense drugs through its Ionis Core segment and wholly owned Akcea Therapeutics subsidiary. The filing covers the three months ended March 31, 2016; financial statements are unaudited and include Akcea. Ionis had 120.8 million shares outstanding as of April 29, 2016.
The principal late-stage programs were nusinersen for spinal muscular atrophy, IONIS-TTR Rx for transthyretin amyloidosis, and volanesorsen for severe lipid disorders. Four of five Phase 3 studies for these programs had completed target enrollment.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Total revenue | $36.9 million | $62.6 million | Down 41% |
| Research and development revenue | $35.2 million | $61.9 million | Down 43% |
| Licensing and royalty revenue | $1.7 million | $0.7 million | Up $1.0 million |
| Operating expenses | $91.5 million | $71.9 million | Up 27% |
| Loss from operations | $54.7 million | $9.3 million | Loss increased |
| Net loss | $62.9 million | $16.7 million | Loss increased |
| Net loss per share | $0.52 | $0.14 | Loss increased |
| Net cash used in operations | $75.8 million | $42.8 million | Use increased |
Reported operating margin was approximately negative 148% versus negative 15% in the prior-year quarter; net margin was approximately negative 171% versus negative 27%. The decline primarily reflected lower milestone-related revenue combined with higher late-stage development costs, Akcea expansion expenses, and increased stock-based compensation.
- Research, development and patent expense was $81.0 million, versus $64.4 million. Excluding non-cash compensation, research, development and patent expense was $66.2 million versus $54.0 million.
- Non-cash stock-based compensation was $20.1 million, up from $13.3 million. Unrecognized expense at March 31, 2016 was $88.9 million for non-vested options and $23.8 million for restricted stock units.
- Investment income was $1.5 million; interest expense was $9.5 million, including substantial non-cash debt discount amortization.
- Cash, cash equivalents and short-term investments totaled $703.8 million at March 31, 2016, down from $779.2 million at December 31, 2015. Working capital was $639.4 million, compared with $688.1 million.
- Cash and cash equivalents were $93.3 million, compared with $128.8 million at year-end. Investing activities provided $39.4 million, primarily from net sales of short-term investments; financing activities provided $0.9 million.
- Total debt and other obligations were $644.7 million. Convertible debt included $500.0 million of 1% notes due 2021 and $61.2 million of 2.75% notes due 2019. The company also had $8.5 million outstanding under a $30 million revolving credit facility at a weighted-average rate of 1.69% and was in compliance with its covenants.
- Total contractual obligations were $756.3 million, including $598.0 million of convertible-note principal and interest obligations and $123.9 million of facility rent payments.
Material changes versus the prior comparable period
- Revenue fell $25.7 million because of the timing and amount of collaboration milestones. Q1 2016 revenue included approximately $15 million of milestone payments, primarily related to nusinersen, compared with a more evenly distributed revenue profile in 2015.
- Operating expenses increased $19.6 million as nusinersen, IONIS-TTR Rx and volanesorsen entered more expensive late-stage development phases and Akcea expanded its development and commercial infrastructure.
- Akcea operating expenses, excluding non-cash compensation, increased to $12.9 million from $6.4 million. Akcea had no revenue.
- Revenue concentration remained high: Biogen represented 58% of Q1 revenue and GSK represented 14%; two significant partners accounted for approximately 98% of contracts receivable.
- Accumulated deficit increased to $1.16 billion from $1.09 billion, while stockholders’ equity decreased to $158.2 million from $200.8 million.
Guidance, outlook, commentary and unusual items
- Management expected Phase 3-related costs to increase modestly during 2016 and Akcea expenses to continue increasing as it prepared for a potential volanesorsen launch within the next couple of years.
- Management stated that financial projections included numerous significant milestone payments in the second half of 2016, making revenue timing inherently volatile. The filing does not provide a clear full-year revenue or earnings forecast.
- Subsequent to quarter-end, Ionis reported $17 million of Q2 revenue, including a $15 million upfront payment from Kastle Therapeutics for global Kynamro rights and a $2 million Biogen milestone for nusinersen. Kastle consideration may total up to $95 million, plus future royalties and a 10% equity position in Kastle’s parent company.
- In May 2016, enrollment was completed in the infant Phase 3 nusinersen study, generating a $2 million milestone. Data from the infant and child Phase 3 studies were expected in the first half of 2017.
- A jury found in favor of Ionis and Merck in the Gilead patent litigation, upholding the asserted claims and awarding the plaintiffs 4% of $5 billion in past sofosbuvir sales. Gilead stated it would appeal; additional validity, damages and ongoing-infringement issues remained unresolved. The ultimate recovery and timing were uncertain.
- Key risks include clinical or regulatory failure, delayed commercialization, dependence on Biogen, GSK and other partners, partner termination rights, manufacturing constraints, intellectual-property disputes, high operating losses, future financing needs, product liability, and market acceptance or reimbursement risk.
Most important facts for investors to verify
- Whether anticipated 2016 milestones and subsequent payments materialize, and whether collaboration revenue can offset rising Phase 3 and Akcea spending.
- Clinical and regulatory results for nusinersen, IONIS-TTR Rx and volanesorsen, including the timing and quality of expected 2017 Phase 3 data.
- Biogen’s and GSK’s option, funding and commercialization decisions, given their substantial contribution to revenue and receivables.
- Liquidity runway relative to the $75.8 million quarterly operating cash burn, $644.7 million of debt and $756.3 million of contractual obligations.
- The outcome, timing and collectability of the Gilead litigation award, including appeals and unresolved damages issues.
- The commercial prospects, regulatory limitations and royalty economics associated with Kynamro following its transfer to Kastle.